Vedolizumab Maintenance Dosing

Standard Dosing Recommendations

The American Gastroenterological Association recommends vedolizumab maintenance therapy every 8 weeks for patients who respond to induction therapy 1, 2
The GEMINI I trial demonstrated no significant difference in efficacy between 4-week and 8-week maintenance dosing for ulcerative colitis, with clinical remission rates of 44.8% vs 41.8% 2
Guidelines explicitly state that "in the absence of controlled data, dose intensification to 4-week dosing is not advocated" 1, 3

Patients with a history of Crohn's disease, such as the patient in question, should have their response to therapy evaluated, including the presence of active infections or tuberculosis, concurrent treatment with other biologics, and immunization status 1, 4

Guidelines recommend evaluating response to vedolizumab induction therapy at 8-14 weeks to determine the need for therapy modification, with patients with Crohn's disease specifically being evaluated between 10-14 weeks 1, 4, 5
Continuing therapy without appropriate monitoring and documentation increases risks without established benefits 1, 4

Patients should be evaluated for symptomatic response to vedolizumab induction therapy at 8-14 weeks, with standard maintenance dosing being every 8 weeks for responders 1, 4
Every 4-week dosing is not routinely recommended by guidelines, and should only be considered with clinical documentation supporting the need for intensification 1, 3, 4